Literature DB >> 33349689

Pembrolizumab can delay progression of TNBC.

David Killock1.   

Abstract

Entities:  

Year:  2020        PMID： 33349689     DOI： 10.1038/s41571-020-00465-x

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  3 in total

1.  Zinc complex of 3,5-di-tert-butyl salicylate inhibits viability, migration, and invasion in triple-negative breast cancer cells.

Authors:  Heng Chen; Dong Wang; Limei Fan; Zixin Liu; Weiran Zhang; Jinhua Xu; Yunyi Liu
Journal:  Sci Rep       Date:  2022-03-16       Impact factor: 4.379

Review 2.  Targeting regulated cell death (RCD) with small-molecule compounds in triple-negative breast cancer: a revisited perspective from molecular mechanisms to targeted therapies.

Authors:  Minru Liao; Rui Qin; Wei Huang; Hong-Ping Zhu; Fu Peng; Bo Han; Bo Liu
Journal:  J Hematol Oncol       Date:  2022-04-12       Impact factor: 17.388

3.  Protein Tyrosine Kinase 7 Regulates EGFR/Akt Signaling Pathway and Correlates With Malignant Progression in Triple-Negative Breast Cancer.

Authors:  Nai-Peng Cui; Shu Qiao; Shan Jiang; Jin-Lin Hu; Ting-Ting Wang; Wen-Wen Liu; Yan Qin; Ya-Nan Wang; Li-Shuang Zheng; Jin-Chao Zhang; Yong-Ping Ma; Bao-Ping Chen; Jian-Hong Shi
Journal:  Front Oncol       Date:  2021-07-22       Impact factor: 6.244
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.